5 Year Capital Spending Growth of PDL BioPharma, Inc. (NASDAQ:PDLI) is reported at 0


Quarterly Sales and EPS Roundup:

PDL BioPharma, Inc. (PDLI) reported sales (ttm) of 186.6 Million, whereas, 2 number of analysts estimated the mean sale of 56.3 million. The analysts estimated sales for the higher end at 66.27 million and lower end at 46.33 million while the year ago reported sale was 0 million.

2 number of analysts have estimated the sales of the company for the quarter ending Aug 2, 2017- Aug 7, 2017, analysts estimated mean sale target of 44.77 million while high and low sale targets are estimated at 49.03 million and 40.51 million respectively.

PDL BioPharma, Inc. (PDLI) reported earning per shares for the quarter ending May 03 AMC at 0.04, whereas, 2 number of analysts estimated the mean EPS at 0.09. The analysts estimated EPS for the higher end at 0.14 and lower end at 0.04 while the year ago reported earnings per share was 0.

The company has mean EPS estimate of 0.04 reported by 2 number of analyst for the quarter ending Aug 2, 2017- Aug 7, 2017. The analysts estimated mean EPS at 0.04 while the high and low EPS estimate stand at 0.05 and 0.03 respectively. In contrast to the year ago quarter EPS was at 0.

Valuation Ratios of PDL BioPharma, Inc. (PDLI) versus the Industry and Sector:

Let’s have a look at some of the important valuation ratios of the PDL BioPharma, Inc. (PDLI). These ratios are important while doing valuation of the company or the shares of the company.

PDL BioPharma, Inc. (PDLI) currently has P/E (Price to Earnings) ratio of 25.6 while the company’s industry has 146.89 P/E and the sector P/E is 17.99. Similarly, the company’s last 5 years high P/E ratio is 5.47 and low P/E is 1.74, whereas, the industry’s and sector’s  high P/E for the past year is 232.74 and 42.93 respectively and low P/E ratio for the last 5 years is 80.29 for the industry and 23.07 for the Sector.

Beta is also an important valuation ratio for analyzing the stock of the company, PDLI has Beta of 0.66 while its industry and Sector’s beta remains at 0.97 and 0.86 respectively.

Price to Sale ratio of PDLI stands at 2.01 while Price to Book Ratio stands at 0.5. Its Price to Cash Flow ratio shows the value of 13, whereas, the industry and sector ratio of Price to Cash Flow ticked at 91.93 and 11.47 respectively.

5 Year Growth Rate Analysis:

Growth rates are very important while analyzing the long term growth and valuation of a certain company.

5 year sales growth rate is an important factor for valuation analysis, the 5 year sales growth of PDL BioPharma, Inc. (PDLI) stands at -7.57 while the industry’s and the sector’s growth for next 5 years ticked at 19.43 and 10.42 respectively. The company’s 5 year Earnings per share growth and Capital Spending growth remains at -6.64 and 0.

PDL BioPharma, Inc. (PDLI) Trading Statistics:

The company surged 2.15% and closed its last trading session at $2.33. The market capitalization of the company is at $379.75 Million. The stock touched 52-week High of $3.77 on 11/15/16 and 52-week Low of $1.93 on 12/20/16. The stock currently has Weekly Volatility of 3.66% and Monthly Volatility of 4.52%. The Beta for the company stands at 0.69 and its Average True Range (ATR) shows a value of 0.1.